Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $129.58 up 4.91% from its previous closing price of $123.52. In other words, the price has increased by $4.91 from its previous closing price. On the day, 0.69 million shares were traded. AXSM stock price reached its highest trading level at $130.35 during the session, while it also had its lowest trading level at $123.42.
Ratios:
For a deeper understanding of Axsome Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.51 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 3.06 whereas as Long-Term Debt/Eq ratio is at 1.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $179.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 06 ’25 when TABUTEAU HERRIOT sold 19,220 shares for $120.17 per share. The transaction valued at 2,309,667 led to the insider holds 7,229 shares of the business.
TABUTEAU HERRIOT sold 13,390 shares of AXSM for $1,590,330 on Oct 07 ’25. The Chief Executive Officer now owns 7,229 shares after completing the transaction at $118.77 per share. On Oct 08 ’25, another insider, TABUTEAU HERRIOT, who serves as the Chief Executive Officer of the company, sold 12,774 shares for $118.84 each. As a result, the insider received 1,518,062 and left with 7,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 6466234880 and an Enterprise Value of 6380525568. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.06 while its Price-to-Book (P/B) ratio in mrq is 88.33. Its current Enterprise Value per Revenue stands at 12.889 whereas that against EBITDA is -31.96.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.49, which has changed by 0.32319224 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $139.13, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 10.10%, while the 200-Day Moving Average is calculated to be 16.74%.
Shares Statistics:
For the past three months, AXSM has traded an average of 559.54K shares per day and 444460 over the past ten days. A total of 49.82M shares are outstanding, with a floating share count of 41.17M. Insiders hold about 17.50% of the company’s shares, while institutions hold 75.91% stake in the company. Shares short for AXSM as of 1759190400 were 3380948 with a Short Ratio of 6.04, compared to 1756425600 on 3509493. Therefore, it implies a Short% of Shares Outstanding of 3380948 and a Short% of Float of 8.08.
Earnings Estimates
The stock of Axsome Therapeutics Inc (AXSM) is currently in the spotlight, with 14.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.23 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$2.97 and -$4.26 for the fiscal current year, implying an average EPS of -$3.71. EPS for the following year is $0.73, with 13.0 analysts recommending between $3.78 and -$2.54.
Revenue Estimates
A total of 19 analysts believe the company’s revenue will be $163.03M this quarter.It ranges from a high estimate of $172.6M to a low estimate of $153.2M. As of. The current estimate, Axsome Therapeutics Inc’s year-ago sales were $104.76MFor the next quarter, 19 analysts are estimating revenue of $185.31M. There is a high estimate of $196.84M for the next quarter, whereas the lowest estimate is $171M.
A total of 20 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $650.02M, while the lowest revenue estimate was $601.1M, resulting in an average revenue estimate of $621.46M. In the same quarter a year ago, actual revenue was $385.69MBased on 20 analysts’ estimates, the company’s revenue will be $966.74M in the next fiscal year. The high estimate is $1.09B and the low estimate is $838.2M.
